{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:18:43Z","timestamp":1790983123607,"version":"4.1.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypophosphatemia is a complex electrolyte disturbance with diverse etiologies, including decreased intestinal absorption, increased renal loss, intracellular redistribution, and medication effects. We present a diagnostically challenging case of severe, persistent hypophosphatemia in a 39-yr-old female with a history of renal transplantation, chronic gastrointestinal disease, and osteoporosis. The patient presented with acute abdominal pain, nausea, and constipation and was found to have profound hypophosphatemia (&amp;lt;0.3\u00a0mmol\/L), hypocalcemia, and hypokalemia. Her recent medical history included administration of i.v. ferric carboxymaltose and denosumab, both known to induce hypophosphatemia via FGF23-mediated renal phosphate wasting and secondary hyperparathyroidism. Additional contributing factors in her case included renal tubular acidosis, tertiary hyperparathyroidism, tacrolimus-induced tubular dysfunction, and significant gastrointestinal losses due to prior bowel resections and acute ileus. Despite aggressive i.v. and oral phosphate supplementation, hypophosphatemia persisted, necessitating prolonged therapy and multiple hospital admissions. Reduction of tacrolimus and correction of acidosis improved phosphate reabsorption, but recurrent episodes highlighted the multifactorial nature of her condition. This case underscores the importance of a systematic, multidisciplinary approach to diagnosing and managing hypophosphatemia, particularly in patients with overlapping risk factors and complex medical histories. Clinicians should maintain a high index of suspicion for delayed and persistent hypophosphatemia in at-risk populations especially following parenteral iron and antiresorptive therapies. Early recognition, regular monitoring, and individualized management are essential to prevent serious complications and improve patient outcomes.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziag121","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:40:15Z","timestamp":1784979615000},"source":"Crossref","is-referenced-by-count":1,"title":["Multifactorial hypophosphatemia: a diagnostic challenge involving denosumab, iron infusion, renal tubular acidosis, and gastrointestinal losses"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3933-4425","authenticated-orcid":false,"given":"Liam","family":"Clifford","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Gosford Hospital , Gosford 2250 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tripti","family":"Joshi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Gosford Hospital , Gosford 2250 ,","place":["Australia"]},{"name":"University of Newcastle , Newcastle 2308 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"2","key":"2026081723021149000_ref1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S2213-8587(19)30426-7","article-title":"Approach to patients with hypophosphataemia","volume":"8","author":"Florenzano","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Supplement_5","key":"2026081723021149000_ref2","doi-asserted-by":"publisher","first-page":"v69","DOI":"10.1093\/jbmrpl\/ziaf014","article-title":"Prevalence, predictors and natural history of hypophosphatemia following iron infusion","volume":"9","author":"Dawson","year":"2025","journal-title":"JBMR Plus"},{"issue":"4","key":"2026081723021149000_ref3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s13730-021-00590-1","article-title":"Refractory hypophosphatemia following ferric carboxymaltose administration","volume":"10","author":"Efe","year":"2021","journal-title":"CEN Case Rep"},{"issue":"4","key":"2026081723021149000_ref4","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/gutjnl-2022-327897","article-title":"Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-\u00ad IBD): a randomised clinical trial","volume":"72","author":"Zoller","year":"2023","journal-title":"Gut"},{"issue":"1","key":"2026081723021149000_ref5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00223-020-00686-3","article-title":"Phosphate metabolism in health and disease","volume":"108","author":"Peacock","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"2026081723021149000_ref6","doi-asserted-by":"publisher","first-page":"116202","DOI":"10.1016\/j.bone.2021.116202","article-title":"Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management","volume":"154","author":"Schaefer","year":"2022","journal-title":"Bone"},{"issue":"5","key":"2026081723021149000_ref7","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of iron Isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"issue":"11","key":"2026081723021149000_ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm9113587","article-title":"A pooled analysis of serum phosphate measurements and potential hypophosphataemia events in 45 interventional trials with ferric carboxymaltose","volume":"9","author":"Rosano","year":"2020","journal-title":"J Clin Med"},{"key":"2026081723021149000_ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-222851","article-title":"Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration","volume":"2018","author":"Klein","year":"2018","journal-title":"BMJ Case Rep"},{"issue":"9\u201310","key":"2026081723021149000_ref10","first-page":"521","article-title":"Hypophosphatemia after treatment with parenteral iron: case report","volume":"90","author":"Mihela\u010d","year":"2021","journal-title":"Slovenian Medical Journal"},{"issue":"3","key":"2026081723021149000_ref11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40264-019-00888-1","article-title":"Drug-induced hypophosphatemia: current insights","volume":"43","author":"Megapanou","year":"2024","journal-title":"Drug Saf"},{"issue":"1","key":"2026081723021149000_ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bcr-2024-263129","article-title":"Severe hypophosphataemia following denosumab administration successfully managed using a calcimimetic agent","volume":"18","author":"Omori","year":"2025","journal-title":"BMJ Case Rep"},{"issue":"7","key":"2026081723021149000_ref13","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1210\/jc.2015-1259","article-title":"Effects of denosumab and calcitriol on severe secondary hyperparathyroidism in dialysis patients with low bone mass","volume":"100","author":"Chen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2026081723021149000_ref14","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1007\/s00198-024-07266-3","article-title":"Denosumab-associated symptomatic hypophosphatemia in normal kidney function: two case reports","volume":"35(12)","author":"Pasquinucci","year":"2024","journal-title":"Osteoporos Int"},{"key":"2026081723021149000_ref15","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.eprac.2022.07.005","article-title":"Hypophosphatemia: a practical guide to evaluation and management","volume":"28(10)","author":"Tebben","year":"2022","journal-title":"Endocr Pract"},{"issue":"6","key":"2026081723021149000_ref16","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/jpen.2006","article-title":"Hypophosphatemia in a specialized intestinal failure unit: an observational cohort study","volume":"45","author":"Eriksen","year":"2020","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"2026081723021149000_ref17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/jlpm-24-35","article-title":"Investigative algorithms for disorders causing hypophosphataemia and hyperphosphataemia: a narrative review","volume":"9(33)","author":"Flowers","year":"2024","journal-title":"J Lab Precis Med"},{"issue":"2","key":"2026081723021149000_ref18","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s12325-020-01587-5","article-title":"Renal tubular acidosis and management strategies: a narrative review","volume":"38","author":"Palmer","year":"2020","journal-title":"Adv Ther"},{"issue":"5","key":"2026081723021149000_ref19","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/j.1600-6143.2007.01753.x","article-title":"Tertiary \u201chyperphosphatoninism\u201d accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients","volume":"7","author":"Evenepoel","year":"2007","journal-title":"Am J Transplant"},{"key":"2026081723021149000_ref20","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/8910092","article-title":"Hypocalcemia and hypophosphatemia following concurrent denosumab injection and ferric carboxymaltose infusion in a patient with Normal renal function","volume":"2024:8910092","author":"Szwarcbard","year":"2024","journal-title":"Case Rep Endocrinol"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziag121\/70267939\/ziag121.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/10\/9\/ziag121\/70267939\/ziag121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/10\/9\/ziag121\/70267939\/ziag121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:02:20Z","timestamp":1787022140000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziag121\/8744126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,10]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziag121","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,28]]},"article-number":"ziag121"}}